Boehringer Ingelheim, IBM partner to expedite antibody discovery
Under the partnership, Boehringer will leverage an AI model developed by IBM, initially pre-trained and subsequently fine-tuned using…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Nov 23
Under the partnership, Boehringer will leverage an AI model developed by IBM, initially pre-trained and subsequently fine-tuned using…
23 Nov 23
The company has designed an AI stack to detect new therapeutic targets and forecast responses of patients to…
22 Nov 23
The partnership is intended to improve Genentech's advanced AI research programmes by converting its generative AI models and…
21 Nov 23
Research aims to employ RION's exosome technology platform to better understand regenerative medicine in war zones for pulmonary…
14 Nov 23
Under the agreement, Aitia will deploy Charles River's Logica across its portfolio of novel drug targets to optimise…
10 Nov 23
The partnership will combine Recursion’s artificial intelligence (AI)-guided drug discovery platform with Bayer’s small molecule compound library and…
09 Nov 23
The goal is to harness the power of large-scale life science models, accelerating the design of AAV vectors,…
08 Nov 23
Under the partnership, both firms will advance the oncology pipeline of condensate modifying therapeutics to Investigational New Drug…
07 Nov 23
Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo…
03 Nov 23
The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame…